Davis Polk advised the joint bookrunners in connection with a Rule 144A offering by The Medicines Company of $402.5 million aggregate principal amount of 2.75% convertible senior notes due 2023, which included $52.5 million aggregate principal amount of notes from the full exercise of the initial purchasers’ option to purchase additional notes.

In addition, Davis Polk advised the counterparties to capped call transactions entered into in connection with the convertible senior notes offering.

Headquartered in Parsippany, New Jersey, The Medicines Company is a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace.

The Davis Polk capital markets team included partner Richard D. Truesdell Jr. and associates Pedro J. Bermeo and Eugene Baek. The Davis Polk equity derivatives team included partner John M. Brandow and associates Robert Stewart and Won Lee. Counsel David R. Bauer provided intellectual property and technology advice. Partner Michael Farber and associate Sarah Joy provided tax advice. The environmental team included counsel Betty Moy Huber. All members of the Davis Polk team are based in the New York office.

Copy link to share post